Apollomics Inc (APLM)

NASDAQ
Currency in USD
5.4500
-0.2500(-4.39%)
Closed·
After Hours
5.1700-0.2800(-5.1376%)
·
APLM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
Day's Range
5.11005.9150
52 wk Range
4.470135.9800
Key Statistics
Edit
Prev. Close
5.45
Open
5.69
Day's Range
5.11-5.915
52 wk Range
4.4701-35.98
Volume
13.37K
Average Volume (3m)
20K
1-Year Change
-72.14%
Book Value / Share
4.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APLM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Apollomics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Apollomics Inc Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.

Compare APLM to Peers and Sector

Metrics to compare
APLM
Peers
Sector
Relationship
P/E Ratio
−0.1x−0.1x−0.5x
PEG Ratio
0.000.000.00
Price/Book
1.2x1.7x2.6x
Price / LTM Sales
30.4x8.4x3.2x
Upside (Analyst Target)
-419.8%45.9%
Fair Value Upside
Unlock16.4%7.0%Unlock

Earnings

Latest Release
Apr 03, 2025
EPS / Forecast
-16.92 / -0.15
Revenue / Forecast
-1,570,000.00 / --
EPS Revisions
Last 90 days

APLM Income Statement

People Also Watch

0.652
ATXG
+1.56%
0.7600
CLDI
-23.85%
2.300
BSLK
-7.63%
0.41
CLIK
-4.67%
1.30
KLTO
-10.96%

FAQ

What Is the Apollomics (APLM) Stock Price Today?

The Apollomics stock price today is 5.45

What Stock Exchange Does Apollomics Trade On?

Apollomics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Apollomics?

The stock symbol for Apollomics is "APLM."

What Is the Apollomics Market Cap?

As of today, Apollomics market cap is 6.01M.

What Is Apollomics's Earnings Per Share (TTM)?

The Apollomics EPS (TTM) is -52.80.

From a Technical Analysis Perspective, Is APLM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Apollomics Stock Split?

Apollomics has split 1 times.

How Many Employees Does Apollomics Have?

Apollomics has 13 employees.

What is the current trading status of Apollomics (APLM)?

As of 14 July 2025, Apollomics (APLM) is trading at a price of 5.45, with a previous close of 5.45. The stock has fluctuated within a day range of 5.11 to 5.92, while its 52-week range spans from 4.47 to 35.98.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.